<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03438474</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OP.6 KKS 228</org_study_id>
    <nct_id>NCT03438474</nct_id>
  </id_info>
  <brief_title>Endometrial Cancer Lymphadenectomy Trial</brief_title>
  <acronym>ECLAT</acronym>
  <official_title>Pelvic and Para-aortic Lymphadenectomy in Patients With Stage I or II Endometrial Cancer With High Risk of Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Aid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this trial is to ascertain whether or not systematic pelvic and
      para-aortic lymphadenectomy (LNE) does have a significant impact on overall survival (OS) in
      patients with endometrial cancer (EC) FIGO Stages I or II and high risk of recurrence.
      Secondary aims will be to evaluate the effect of LNE on disease free survival (DFS) and
      quality of life, as well as the complications and side effects of LNE and the number of
      resected lymphnodes. 640 patients with histologically confirmed EC with high risk of
      recurrence (stage pT1b - pT2, all histological subtypes; pT1a, G3 endometrioid or serous or
      clear cell EC or carcinosarcomas) will be randomized. In Arm A, a total hysterectomy and
      bilateral salpingo-oophorectomy and in case of serous or clear cell EC additionally an
      omentectomy will be performed. In arm B in addition a systematic pelvic and para-aortic LNE
      up to the level of the left renal vein will be performed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">February 15, 2029</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>60 months</time_frame>
    <description>Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on overall survival in EC patients with high risk of recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months</time_frame>
    <description>Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on Disease free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease specific survival (DSS)</measure>
    <time_frame>3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months</time_frame>
    <description>Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on Disease specific survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of serious complications</measure>
    <time_frame>during surgery, at hospital discharge, day 60, 6 months, 9 months, 12 months</time_frame>
    <description>Assessment of perioperative complications and site effects of LNE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months</time_frame>
    <description>Health related Quality of life (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-EN24</measure>
    <time_frame>Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months</time_frame>
    <description>Health related Quality of life (QoL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of resected lymph nodes</measure>
    <time_frame>during surgery</time_frame>
    <description>resected pelvic and para-aortic lymph nodes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Cancer of Endometrium Stage I</condition>
  <condition>Cancer of Endometrium Stage II</condition>
  <arm_group>
    <arm_group_label>Arm A standard surgical procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard surgical procedure for endometrial cancer:
total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B systematic lymphadenectomy (LNE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to standard procedures as defined for Arm A:
systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard surgical procedure for endometrial cancer</intervention_name>
    <description>total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)</description>
    <arm_group_label>Arm A standard surgical procedure</arm_group_label>
    <arm_group_label>Arm B systematic lymphadenectomy (LNE)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>systematic lymphadenectomy (LNE)</intervention_name>
    <description>systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels</description>
    <arm_group_label>Arm B systematic lymphadenectomy (LNE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically confirmed EC of clinical stages T1b and T2 (all histological types) and
             stage T1a G3 type 1 (endometrioid, endometriod with squamous differentiation,
             mucinous) or type 2 tumors (any percentage of serous or clear cell component) or
             carcinosarcoma

          2. a) no previous surgery concerning EC (primary surgery) or b) surgery after
             hysterectomy (e.g. for presumed low risk endometrial cancer) is allowed within 8 weeks
             after hysterectomy if no LNE was performed (secondary surgery)

          3. absence of bulky lymph nodes

          4. performance status ECOG 0-1

          5. age 18 - 75 years

          6. written informed consent

          7. adequate compliance

        Exclusion Criteria:

          1. stage pT1a, G1 or G2 tumors of type 1 histology

          2. sarcomas (except for carcinosarcoma = malignant mixed Müllerian tumor)

          3. EC of FIGO stages III or IV (except for microscopical lymph node metastases)

          4. evidence of extrauterine disease by visual inspection

          5. recurrent EC

          6. preceding chemo-, radio, or endocrine therapy for EC

          7. any concomitant disease not allowing surgery including lymphadenectomy and/or
             chemotherapy

          8. any medical history indicating excessive peri-operative risk

          9. any current medication containing considerable surgical risk (e.g. bleeding: due to
             oral anticoagulating agents)

         10. any known disorder or circumstances making participation in trial and follow-up
             questionable. Insufficient compliance is expected.

         11. patients with second malignancies if disease or treatment might have an impact on the
             patient's prognosis

         12. known HIV-infection or AIDS

         13. simultaneous participation in other clinical trials if not permitted by the steering
             committee (translational or QoL studies not interfering with the objectives of ECLAT
             are allowed)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Günter Emons, Professor MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Göttingen, Georg-August-Universität, Universitätsfrauenklinik</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Günter Emons, Professor MD</last_name>
    <phone>0049 (0) 551-3966501</phone>
    <email>emons@med.uni-goettingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Harter, MD</last_name>
    <phone>0049 (0) 201 1743-4511</phone>
    <email>p.harter@kliniken-essen-mitte.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kliniken Essen Mitte, Evang. Huyssens Stiftung/Knappschaft GmbH, Gynäkologische Onkologie</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Harter, MD</last_name>
      <phone>0049 (0) 201 1743-4511</phone>
      <email>p.harter@kliniken-essen-mitte.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Göttingen, Georg-August-Universität, Universitätsfrauenklinik</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Günter Emons, Professor MD</last_name>
      <phone>0049 (0) 551-3966501</phone>
      <email>emons@med.uni-goettingen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

